Company intelligence / Profile preview

Marie Uniq

Osaka, Osaka, Japan

Ownership: Private
Development stage: Other

Overview

Marie Uniq is a Japanese biotechnology company specializing in the development of advanced cell culture systems for regenerative medicine. The company's flagship technology is a closed-system cell culture vessel designed to minimize contamination risks and improve the efficiency of cell therapy manufacturing. By providing automated and scalable solutions for cell expansion, Marie Uniq supports the clinical and commercial development of cell-based therapies. Their products are primarily used by research institutions and pharmaceutical companies focused on regenerative medicine and immunotherapy.

Modalities: Cell therapy
Industry: Non-Drug Biotech

Partnerships

Osaka University

Beyond the preview

Go deeper on Marie Uniq.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marie Uniq.

Explore the full profile